Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Current Deferred Revenue (2017 - 2020)

Serina Therapeutics' Current Deferred Revenue history spans 4 years, with the latest figure at $300000.0 for Q4 2020.

  • For Q4 2020, Current Deferred Revenue rose 6.01% year-over-year to $300000.0; the TTM value through Dec 2020 reached $300000.0, up 6.01%, while the annual FY2020 figure was $300000.0, 6.01% up from the prior year.
  • Current Deferred Revenue for Q4 2020 was $300000.0 at Serina Therapeutics, up from $255000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $407000.0 in Q1 2020 and bottomed at $180000.0 in Q4 2017.
  • The 4-year median for Current Deferred Revenue is $283000.0 (2019), against an average of $283888.9.
  • The largest annual shift saw Current Deferred Revenue surged 76.11% in 2018 before it decreased 10.73% in 2019.
  • A 4-year view of Current Deferred Revenue shows it stood at $180000.0 in 2017, then soared by 76.11% to $317000.0 in 2018, then fell by 10.73% to $283000.0 in 2019, then grew by 6.01% to $300000.0 in 2020.
  • Per Business Quant, the three most recent readings for SER's Current Deferred Revenue are $300000.0 (Q4 2020), $255000.0 (Q3 2020), and $328000.0 (Q2 2020).